Helus Pharma remains a buy, as HLP003's Phase 3 APPROACH topline data in 4Q26 is the key near-term catalyst. HLP003 targets adjunctive MDD with a differentiated intermittent dosing model; prior Phase 2 data showed a 23-point MADRS reduction and 71% remission at 12 months. HELP's $166.4M cash balance provides 12–14 months runway, but dilution risk persists given high operating outflows and the $100M ATM facility.
Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen's Novel Mechanisms in Neuropsychiatry virtual summit.
Helus Pharma has built a proprietary psychedelic pipeline that currently spans MDD and GAD. The company has two clinical-stage assets and a broader serotonergic discovery platform. Early HLP003 (oral psilocin) and HLP004 (IM DMT) data suggest efficacy and durability when used as adjunctive therapies, although this comes from small trials. Helus is conducting a phase III trial for HLP003, which could validate its clinical profile and reduce the valuation discount relative to peers.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Christopher C. Powers Farther Finance Advisors, LLC | 1,199 | $3,021 | $3,573.02 | $552.02 | 18.27% |
| Metals & Mining Industry | Materials Sector | Jie Liu CEO | NASDAQ (CM) Exchange | G4594M108 CUSIP |
| CN Country | 167 Employees | - Last Dividend | - Last Split | - IPO Date |
Hongli Group Inc., founded in 2021, is a prominent entity headquartered in Weifang, China, that operates globally. The company, functioning through its subsidiaries, has carved a niche in the design, customization, manufacturing, and sales of cold roll formed steel profiles. These products find their applications across a broad spectrum of industries such as mining and excavation, construction, agriculture, and transportation. With a geographic reach that extends to the People's Republic of China, South Korea, Japan, the United States, and Sweden, Hongli Group Inc. demonstrates a global footprint in the industrial manufacturing sector. As a subsidiary of Hongli Development Limited, the group leverages synergies within its corporate structure to drive innovation and cater to a diverse client base worldwide.